Novartis Pharma Schweiz AG - Tafinlar 50 mg, Hartkapseln | | 62781 | | 01 | | Tafinlar 50 mg | | Hartkapseln | | L01EC02 | | Dabrafenib | | 13.01.2014 | | |
| Composition | dabrafenibum 50 mg ut dabrafenibi mesilas, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, Kapselhülle: hypromellosum, E 171, E 172 (rubrum), Drucktinte: lacca, E 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. | Packungsbestandteile | | Capsules | | | Principe actif | Concentr. |
---|
Dabrafenibum | 50 mg |
| BAG: Principe actif | Concentr. |
---|
Dabrafenibum | 50 mg |
| | Agents auxilliaires | | informations additionels |
---|
(Nigrum) | | | (Rubrum) | | | Ammonii Hydroxidum | | | Cellulosum Microcristallinum | | | E 171 | | color. | E 172 | | color. | Hypromellosum | | Kapselhülle | Lacca | | Drucktinte | Magnesii Stearas | | | Pro Capsula | | | Propylenglycol | | | Silica Colloidalis Anhydrica | | |
| |
| |
|